Your browser doesn't support javascript.
loading
Thyroid dysfunction following vaccination with COVID-19 vaccines: a basic review of the preliminary evidence.
Jafarzadeh, A; Nemati, M; Jafarzadeh, S; Nozari, P; Mortazavi, S M J.
Afiliação
  • Jafarzadeh A; Department of Immunology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran. Jafarzadeh14@yahoo.com.
  • Nemati M; Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. Jafarzadeh14@yahoo.com.
  • Jafarzadeh S; Department of Immunology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. Jafarzadeh14@yahoo.com.
  • Nozari P; Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
  • Mortazavi SMJ; Department of Haematology and Laboratory Sciences, School of Para-Medicine, Kerman University of Medical Sciences, Kerman, Iran.
J Endocrinol Invest ; 45(10): 1835-1863, 2022 Oct.
Article em En | MEDLINE | ID: mdl-35347651
PURPOSE: The safety and efficacy of the several types of COVID-19 vaccines, including mRNA-based, viral vector-based, and inactivated vaccines, have been approved by WHO. The vaccines can confer protection against severe SARS-CoV-2 infection through induction of the anti-spike protein neutralizing antibodies. However, SARS-CoV-2 vaccines have been associated with very rare complications, such as thyroid disorders. This review was conducted to highlight main features of thyroid abnormalities following COVID-19 vaccination. METHODS: A comprehensive search within electronic databases was performed to collect reports of thyroid disorders after vaccination with COVID-19 vaccines. RESULTS: Among 83 reported cases including in this review, the most cases of thyroid abnormalities were observed after vaccination with mRNA-based vaccines (68.7%), followed by viral vector vaccines (15.7%) and 14.5% cases following inactivated vaccines. Subacute thyroiditis (SAT) was the most common COVID-19 vaccination-related thyroid disease, accounting for 60.2% of all cases, followed by Graves' disease (GD) with 25.3%. Moreover, some cases with focal painful thyroiditis (3.6%), silent thyroiditis (3.6%), concurrent GD and SAT (2.4%), thyroid eye disease (1.2%), overt hypothyroidism (1.2%), atypical subacute thyroiditis (1.2%), and painless thyroiditis with TPP (1.2%) were also reported. Overall, in 58.0% of SAT cases and in 61.9% of GD cases, the onset of the symptoms occurred following the first vaccine dose with a median of 10.0 days (ranged: 3-21 days) and 10.0 days (ranged: 1-60 days) after vaccination, respectively. Moreover, 40.0% of SAT patients and 38.1% of GD patients developed the symptoms after the second dose with a median of 10.5 days (ranged: 0.5-37 days) and 14.0 days (ranged: 2-35 days) after vaccination, respectively. CONCLUSION: Fortunately, almost all cases with COVID-19 vaccination-associated thyroid dysfunctions had a favorable outcome following therapy. The benefits of COVID-19 vaccinations in terms of terminating the pandemic and/or reducing mortality rates can exceed any risk of infrequent complications such as a transient thyroid malfunction.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças da Glândula Tireoide / Vacinas contra COVID-19 Limite: Humans Idioma: En Revista: J Endocrinol Invest Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Irã País de publicação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças da Glândula Tireoide / Vacinas contra COVID-19 Limite: Humans Idioma: En Revista: J Endocrinol Invest Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Irã País de publicação: Itália